keyword
MENU ▼
Read by QxMD icon Read
search

interferon beta-1a

keyword
https://www.readbyqxmd.com/read/29862891/%C3%AE-linolenic-acid-is-associated-with-mri-activity-in-a-prospective-cohort-of-multiple-sclerosis-patients
#1
Kjetil Bjornevik, Kjell-Morten Myhr, Antonie Beiske, Kristian S Bjerve, Trygve Holmøy, Harald Hovdal, Rune Midgard, Trond Riise, Stig Wergeland, Øivind Torkildsen
BACKGROUND: The plant-based ω-3 fatty acid α-linolenic acid (ALA) has been associated with lower MS risk. It is currently unknown whether ALA affects disease activity. OBJECTIVE: To investigate the association between ALA levels and disease activity. METHODS: We conducted a cohort study including 87 multiple sclerosis (MS)-patients who originally participated in a randomized trial of ω-3 fatty acids (the OFAMS study). We measured serum levels of ALA during follow-up and used random intercept logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CIs) for the association between ALA levels, new magnetic resonance imaging (MRI) lesions, Expanded Disability Status Scale (EDSS) progression and new relapses adjusting for age at inclusion, sex, and use of interferon beta-1a...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29774057/ocrelizumab-a-new-milestone-in-multiple-sclerosis-therapy
#2
REVIEW
Patricia Mulero, Luciana Midaglia, Xavier Montalban
B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in the activation of pro-inflammatory T cells, secretion of pro-inflammatory cytokines and production of autoantibodies directed against myelin. Hence, the use of B cell-depleting monoclonal antibodies as therapy for autoimmune diseases, including MS, has increased in recent years. Previous results with rituximab, the first therapeutic B cell-depleting chimeric monoclonal antibody that showed efficacy in MS clinical trials, encouraged researchers to evaluate the efficacy of a humanized anti-CD20 antibody, ocrelizumab, in MS...
2018: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/29751787/predictive-value-of-early-magnetic-resonance-imaging-measures-is-differentially-affected-by-the-dose-of-interferon-beta-1a-given-subcutaneously-three-times-a-week-an-exploratory-analysis-of-the-prisms-study
#3
Anthony Traboulsee, David K B Li, Mark Cascione, Juanzhi Fang, Fernando Dangond, Aaron Miller
BACKGROUND: On-treatment magnetic resonance imaging lesions may predict long-term clinical outcomes in patients receiving interferon β-1a. This study aimed to assess the effect of active T2 and T1 gadolinium-enhancing (Gd+) lesions on relapses and 3-month confirmed Expanded Disability Status Scale (EDSS) progression in the PRISMS clinical trial. METHODS: Exploratory analyses assessed whether active T2 and T1 Gd + lesions at Month 6, or active T2 lesions at Month 12, predicted clinical outcomes over 4 years in PRISMS...
May 11, 2018: BMC Neurology
https://www.readbyqxmd.com/read/29720872/adherence-to-subcutaneous-interferon-beta-1a-treatment-using-an-electronic-injection-device-a-prospective-open-label-scandinavian-noninterventional-study-the-scansmart-study
#4
Elena Didenko Pedersen, Egon Stenager, J L Vadgaard, M B Jensen, R Schmid, N Meland, G Magnussen, Jette L Frederiksen
Background: Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes. Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart® and assess injection-site reactions and treatment satisfaction. Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS...
2018: Patient Preference and Adherence
https://www.readbyqxmd.com/read/29679749/matching-adjusted-comparisons-demonstrate-better-clinical-outcomes-with-sc-peginterferon-beta-1a-every-two-weeks-than-with-sc-interferon-beta-1a-three-times-per-week
#5
Patricia K Coyle, Shulian Shang, Zhen Xiao, Qunming Dong, Carmen Castrillo-Viguera
BACKGROUND: Subcutaneous (SC) peginterferon beta-1a and SC interferon beta-1a (IFN beta-1a) have demonstrated efficacy in treating relapsing-remitting multiple sclerosis (RRMS) but have never been compared in direct head-to-head clinical trials, the gold-standard comparison. A well-balanced matching-adjusted comparison of weighted individual patient data on SC peginterferon beta-1a, and aggregate data from published phase 3 clinical trials of SC IFN beta-1a, was conducted to provide additional information on the comparative efficacy of these two agents...
May 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29674057/high-resolution-glycoform-profiling-of-intact-therapeutic-proteins-by-hydrophilic-interaction-chromatography-mass-spectrometry
#6
Elena Domínguez-Vega, Sara Tengattini, Claudia Peintner, Jordy van Angeren, Caterina Temporini, Rob Haselberg, Gabriella Massolini, Govert W Somsen
Glycosylation is considered a critical quality attribute of therapeutic proteins. Protein heterogeneity introduced by glycosylation includes differences in the nature, number and position of the glycans. Whereas analysis of released glycans and glycopeptides provides information about the composition and/or position of the glycan, intact glycoprotein analysis allows assignment of individual proteoforms and co-occurring modifications. Yet, resolving protein glycoforms at the intact level is challenging. We have explored the capacity of hydrophilic liquid chromatography-mass spectrometry (HILIC-MS) for assessing glycosylation patterns of intact pharmaceutical proteins by analyzing the complex glycoproteins interferon-beta-1a (rhIFN-β - 1a) and recombinant human erythropoietin (rhEPO)...
July 1, 2018: Talanta
https://www.readbyqxmd.com/read/29671656/interferon-beta-injection-site-reactions-in-patients-with-multiple-sclerosis
#7
Martina Maurelli, Roberto Bergamaschi, Ambra Antonini, Maria Concetta Fargnoli, Elisa Puma, Giulia Mallucci, Rocco Totaro, Giampiero Girolomoni
Interferon-beta (IFNβ) is effective treatments for relapsing multiple sclerosis (MS). IFNβ treatment includes subcutaneous (SC) IFNβ-1b, intramuscular (IM) and SC IFNβ-1a, and SC pegylated IFNβ-1a (PEG-IFNβ-1a). PEG-IFNβ-1a offers the advantage of a prolonged duration of action with a less frequent administration (every 2 weeks) and a higher patient adherence. However, the use of SC interferons could be characterized by potential skin toxicity. Injection site reactions (ISRs), featured by erythema, edema, pain, and pruritus, are the most common adverse reactions...
May 7, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29645071/daclizumab-in-multiple-sclerosis
#8
REVIEW
F C Perez-Miralles
INTRODUCTION: Daclizumab is a monoclonal antibody directed against the CD25 subunit of the interleukin-2 receptor, investigated as a disease-modifying therapy in relapsing-remitting multiple sclerosis. The present review addresses how the drug was developed, the known mechanism of action of the drug and the up-to-date data of efficacy and safety. DEVELOPMENT: Daclizumab has shown superiority in prevention of relapses against placebo and low-dose interferon beta-1a at a level that puts it on par with the rest of current first-line drugs...
April 16, 2018: Revista de Neurologia
https://www.readbyqxmd.com/read/29607711/pediatric-multiple-sclerosis-in-the-united-arab-emirates-characteristics-from-a-multicenter-study-and-global-comparison
#9
Fatima Y Ismail, Eliza Gordon-Lipkin, Katherine Huether, Iain Blair, Miklós Szólics, Taoufik Alsaadi, Faisal Aziz, Jehan Suleiman, Nicoline Schiess
We delineate the clinical characteristics, incidence, and prevalence of pediatric-onset multiple sclerosis in Abu Dhabi, United Arab Emirates, from 2010 to 2014. Eighty-two patients (65% female) were identified. Fifty-three (64.6%) were Emiratis (45 from Abu Dhabi and 8 from 5 other emirates) and 29 were expatriates. Mean age of onset was 15.9 years overall, 15.3 years in males and 16.3 years in females. Patients with onset before age 12 years presented with visual symptoms while those with onset after age 12 years presented with a mixture of visual, motor and sensory symptoms...
May 2018: Journal of Child Neurology
https://www.readbyqxmd.com/read/29589548/characterization-of-regulatory-t-cells-in-multiple-sclerosis-patients-treated-with-interferon-beta-1a
#10
Mohsen Ebrahimi, Ali Ganji, Sarah Zahedi, Parisa Nourbakhsh, Keyvan Ghasami, Ghasem Mosayebi
BACKGROUND: Regulatory T-Cells (Treg Cells), as one of the immune system components, have been highly effective in the autoimmune diseases prevention, particularly multiple sclerosis (MS). Cytokine-based therapies such as interferon beta-1a (IFN-β1a) is a common drug in MS treatment; however, its exact mechanisms are insufficiently described. OBJECTIVE: Therefore, the goal of this study was to evaluate the in vivo impact of IFN-β1a on the Treg Cells in MS. METHODS: In this case-control study, Treg Cells were analysed by flowcytometry in IFN-β1a-treated relapsing-remitting MS (RRMS) in comparison with new cases of MS and healthy subjects...
March 27, 2018: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/29568544/no-evidence-of-disease-activity-neda-analysis-by-epochs-in-patients-with-relapsing-multiple-sclerosis-treated-with-ocrelizumab-vs-interferon-beta-1a
#11
Eva Havrdová, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Hans-Peter Hartung, Ludwig Kappos, Fred Lublin, Krzysztof Selmaj, Anthony Traboulsee, Shibeshih Belachew, Iain Bennett, Regine Buffels, Hideki Garren, Jian Han, Laura Julian, Julie Napieralski, Stephen L Hauser, Gavin Giovannoni
Background: No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosis (MS). Objective: The objective of this paper is to assess the effect of ocrelizumab on NEDA using re-baselining analysis, and the predictive value of NEDA status. Methods: NEDA was assessed in a modified intent-to-treat population ( n  = 1520) from the pooled OPERA I and OPERA II studies over various epochs in patients with relapsing MS receiving ocrelizumab (600 mg) or interferon beta-1a (IFN β-1a; 44 μg)...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29526118/first-line-disease-modifying-drugs-in-relapsing-remitting-multiple-sclerosis-an-italian-real-life-multicenter-study-on-persistence
#12
Diana Ferraro, Valentina Camera, Eleonora Baldi, Veria Vacchiano, Erica Curti, Angelica Guareschi, Susanna Malagù, Sara Montepietra, Silvia Strumia, Mario Santangelo, Luisa Caniatti, Matteo Foschi, Alessandra Lugaresi, Franco Granella, Ilaria Pesci, Luisa Motti, Walter Neri, Paolo Immovilli, Enrico Montanari, Francesca Vitetta, Anna Maria Simone, Patrizia Sola
OBJECTIVE: The introduction of oral disease-modifying drugs (DMDs) in addition to the available, injectable, ones for relapsing-remitting multiple sclerosis (RRMS) could be expected to improve medication persistence due to a greater acceptability of the route of administration. The aim of the study was to compare the proportion of patients discontinuing injectable DMDs (interferon beta 1a/1b, pegylated interferon, glatiramer acetate) with those discontinuing oral DMDs (dimethylfumarate and teriflunomide) during an observation period of at least 12 months...
April 12, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29525836/monitoring-and-management-of-autoimmunity-in-multiple-sclerosis-patients-treated-with-alemtuzumab-practical-recommendations
#13
REVIEW
Virginia Devonshire, Richard Phillips, Hilary Wass, Gerald Da Roza, Peter Senior
Alemtuzumab is a humanized anti-CD52 monoclonal antibody approved in more than 65 countries for the treatment of relapsing-remitting multiple sclerosis (RRMS). Compared with subcutaneous interferon-beta-1a, alemtuzumab significantly reduced clinical disease activity and the rate of brain volume loss, and improved disability outcomes in patients with active RRMS who were either treatment naive (CARE-MS I study) or who had an inadequate response (≥ 1 relapse after ≥ 6 months of treatment) to prior therapy (CARE-MS II study)...
March 10, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29504299/neutralizing-antibodies-against-interferon-beta-in-korean-patients-with-multiple-sclerosis
#14
Jae Won Hyun, Gayoung Kim, Yeseul Kim, Byungsoo Kong, AeRan Joung, Na Young Park, Hyunmin Jang, Hyun June Shin, Su Hyun Kim, Suk Won Ahn, Ha Young Shin, So Young Huh, Woojun Kim, Min Su Park, Byung Jo Kim, Byoung Joon Kim, Jeeyoung Oh, Ho Jin Kim
BACKGROUND AND PURPOSE: Patients treated with interferon-beta (IFN-β) can develop neutralizing antibodies (NAbs) against IFN-β that can negatively affect the therapeutic response. This study assessed the prevalence of NAbs and the impact of NAb positivity on the therapeutic response to IFN-β in Korean patients with multiple sclerosis (MS). METHODS: This was a multicenter study involving 150 MS patients from 9 Korean medical centers who were treated with IFN-β for at least 6 months...
April 2018: Journal of Clinical Neurology
https://www.readbyqxmd.com/read/29484976/new-life-to-an-old-treatment-pegylated-interferon-beta-1a-in-the-management-of-multiple-sclerosis
#15
Miguel Angel Ortiz, Laura Espino-Paisan, Concepcion Nunez, Roberto Alvarez-Lafuente, Elena Urcelay
In the 1990s, the betainterferons and glatiramer acetate were introduced for treating relapsing-remitting multiple sclerosis. These medications have a demonstrated record of efficacy and safety, although they require frequent administration via injection and are only partially effective. The optimization of treatment in patients who do not respond adequately to this first-line therapy is essential for attaining the best long-term outcomes. Switching to the recently approved emergent therapies is a strategy to consider for treatment of patients with a suboptimal response...
February 25, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29458918/management-of-ifn-beta-induced-flu-like-symptoms-with-chinese-herbal-medicine-in-a-patient-with-multiple-sclerosis-a-case-report
#16
Li-Wen Lee, Hung-Jen Lin, Sheng-Teng Huang
OBJECTIVE: The purpose of this case report was to elucidate how Chinese herbal medicine (CHM) was used safely in this patient undergoing interferon beta (IFNβ-1a) treatment and was associated with reduction in the side effects the patient had experienced when using IFNβ-1a treatment alone. CLINICAL FEATURES AND OUTCOME: A 30-year-old man was diagnosed with MS in December 2014. For two years, he suffered from severe flu-like symptoms as side effects of IFNβ-1a treatment...
February 2018: Complementary Therapies in Medicine
https://www.readbyqxmd.com/read/29318902/interferon-%C3%AE-1a-and-%C3%AE-1b-for-patients-with-multiple-sclerosis-updates-to-current-knowledge
#17
Uwe Klaus Zettl, Michael Hecker, Orhan Aktas, Torsten Wagner, Paulus S Rommer
Although multiple sclerosis (MS) remains incurable, interferon beta (IFNβ) has been at the forefront of treatment for many years. Different formulations of IFNβ allow for different levels of exposure: low-dose/frequency with some agents, and high-dose/frequency with others. Areas covered: This review article discusses existing and emerging efficacy and safety data for IFNβ in MS. Clinical evidence of IFNβ efficacy has been generated and accumulated over many decades. During this time, key clinical trials have demonstrated the benefits of high-dose and/or high-frequency dosing of IFNβ-1a or β-1b, compared with lower levels of exposure, on outcome measures such as relapse rates, disability progression, disease progression and magnetic resonance imaging lesion outcomes...
February 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29317954/a-multiple-treatment-comparison-of-eleven-disease-modifying-drugs-used-for-multiple-sclerosis
#18
Vida Hamidi, Elisabeth Couto, Tove Ringerike, Marianne Klemp
Background: Several disease-modifying drug therapies are available for the treatment of multiple sclerosis (MS). To ensure the most appropriate MS management, we assessed the effectiveness and cost-effectiveness of the disease-modifying medicines used for MS. Methods: We conducted a systematic review including 11 disease-modifying drugs used for treatment of adult patients diagnosed with relapsing-remitting MS. We performed a network meta-analysis using both direct and indirect evidence...
February 2018: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/29249139/omalizumab-for-refractory-chronic-spontaneous-urticaria-during-concurrent-immunomodulatory-therapy-for-multiple-sclerosis
#19
N Syrigos, D Grapsa, E Syrigou
Data derived from previous clinical trials and real-life studies have shown that omalizumab may represent an effective third-line treatment option for patients with chronic spontaneous urticaria (CSU) refractory to standard antihistamine treatment. Nevertheless, the safety and efficacy of omalizumab treatment for CSU, when administered concurrently with other immunomodulatory agents remains largely unknown. We herein present the case of a female patient with relapsing-remitting multiple sclerosis (RRMS), under treatment with interferon beta-1a, azathioprine and gabapentin, who was successfully treated with omalizumab for refractory CSU...
November 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29209636/neurofilament-light-chain-predicts-disease-activity-in-relapsing-remitting-ms
#20
Kristin N Varhaug, Christian Barro, Kjetil Bjørnevik, Kjell-Morten Myhr, Øivind Torkildsen, Stig Wergeland, Laurence A Bindoff, Jens Kuhle, Christian Vedeler
Objective: To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-like 1 (CHI3L1) predict disease activity in relapsing-remitting MS (RRMS). Methods: A cohort of 85 patients with RRMS were followed for 2 years (6 months without disease-modifying treatment and 18 months with interferon-beta 1a [IFNB-1a]). Expanded Disability Status Scale was scored at baseline and every 6 months thereafter. MRI was performed at baseline and monthly for 9 months and then at months 12 and 24...
January 2018: Neurology® Neuroimmunology & Neuroinflammation
keyword
keyword
80155
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"